Brokerages Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) PT at $75.00

by · The Markets Daily

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) have been assigned a consensus rating of “Hold” from the six analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $75.00.

Separately, Wall Street Zen raised shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, July 5th.

Check Out Our Latest Report on Reviva Pharmaceuticals

Hedge Funds Weigh In On Reviva Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. NewEdge Advisors LLC acquired a new stake in shares of Reviva Pharmaceuticals during the 1st quarter worth $58,000. Geode Capital Management LLC boosted its holdings in Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after acquiring an additional 29,063 shares during the last quarter. XTX Topco Ltd purchased a new stake in Reviva Pharmaceuticals during the second quarter valued at about $31,000. Armistice Capital LLC acquired a new stake in Reviva Pharmaceuticals during the second quarter worth about $1,026,000. Finally, Lido Advisors LLC acquired a new position in shares of Reviva Pharmaceuticals in the 3rd quarter valued at about $37,000. Institutional investors and hedge funds own 63.18% of the company’s stock.

Reviva Pharmaceuticals Trading Down 1.9%

Shares of NASDAQ:RVPH opened at $0.53 on Thursday. The stock’s 50-day moving average price is $0.51 and its two-hundred day moving average price is $1.15. Reviva Pharmaceuticals has a 12-month low of $0.26 and a 12-month high of $17.20. The firm has a market cap of $6.95 million, a price-to-earnings ratio of -0.29 and a beta of 0.50.

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.19. As a group, research analysts forecast that Reviva Pharmaceuticals will post -2.96 earnings per share for the current fiscal year.

Reviva Pharmaceuticals Company Profile

(Get Free Report)

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.

Featured Stories